Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 12, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume per Executive | Exchange |
|---|---|---|---|---|
| July 11, 2017 | Ordinary Shares (25p each) | £16.0407 | 16 Shares | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of Ordinary Shares under the Company's Share Reward Plan by ten senior executives. Each transaction consisted of 8 partnership shares and 8 matching shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of specific equity transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions under the Share Reward Plan, not open market sales or purchases.
- Executives Involved: Transactions were executed by the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and eight other senior officers including the President of Global Pharmaceuticals and President of R&D.
- Volume: The total volume per executive was minimal (16 shares), indicating these are likely vesting or matching contributions rather than significant discretionary trading.
- Price Consistency: All transactions occurred at the identical price of £16.0407 on the same date.